TTrialPathMatch Me to Trials
← Back to trials
RecruitingPrimary Ovarian InsufficiencyPremature MenopauseMetabolic Complications

Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency

Eligible age

30–40 yrs

Accepts

Women

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this observational study is to study the effects of treating women with Primary Ovarian Insufficiency (POI) with estrogen replacement therapy to bolster the evidence backing cardiometabolic preventive care in women with POI. The main question it aims to answer is: Does 6 months of estrogen replacement therapy for women with POI improved markers of heart health? Women newly diagnosed with POI (within 6 months) who are planning to start estrogen replacement therapy from their clinical provider will undergo assessment of markers of heart health before and after 6 months of treatment. These markers will also be compared to those obtained from healthy women without POI.

Sponsor: Massachusetts General Hospital

You may qualify if…

  • ✓ female sex
  • ✓ age 30-40
  • ✓ CASE PARTICIPANTS ONLY: clinically documented POI diagnosis within 6 months
  • ✓ CASE PARTICIPANTS ONLY: planning to clinically initiate 100mcg transdermal 17beta-estradiol twice weekly and micro-ionized progesterone (either 100mg daily or 200mg cyclically)
  • ✓ CONTROL PARTICIPANTS ONLY: regular menstrual cycles every 21-35 days

You may not qualify if…

  • ✕ CASE PARTICIPANTS ONLY: genetic POI etiology
  • ✕ CASE PARTICIPANTS ONLY: any prior initiation of ERT
  • ✕ systemic estrogen, progesterone or testosterone therapy within the past 6 months (including contraception, except for locally acting intrauterine devices - IUDs)
  • ✕ lipid lowering therapy within the past 6 months
  • ✕ use of antihypertensive medication within the past 6 months
  • ✕ current treatment with prescription, systemic (oral, IV, or IM) steroids or anti-inflammatory/immune suppressant medical therapies (excluding topical therapies, UV therapy, ASA-derivative therapies, or NSAIDS) for autoimmune/inflammatory diseases (psoriasis, RA, IBD, lupus), post-transplant care, asthma, or pain syndromes
  • ✕ use of oral steroids or prescription oral anti-inflammatory/immune suppressant medication for \>7 days within the past 1 month
  • ✕ use of IV or IM steroids or IV or IM anti-inflammatory/immune suppressant medication within the past 3 months

Where it's recruiting

Source: ClinicalTrials.gov · NCT06866119 · last updated 2026-09-08

Effects of Estrogen on Heart Health in Women With Primary Ovarian Insu · TrialPath